LMO1 is implicated as an independent predictor of poor patient survival in the clinic [36] and its co-expression with MYCN was associated with an earlier onset and increased penetrance of neuroblastoma [37], indicating that the inhibition of MYCN might lead to a concomitant decrease of LMO1. Here, LMO1 is linked to neuroblastoma.